Jiangsu Vcare Approved to Establish "Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"

VC005 Topical Gel is to Launch Phase III Trials! Jiangsu Vcare’s Fourth Independently Developed Innovative Drug will enter the Confirmatory Clinical Stage

Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has received ethical approval for its Phase III clinical trial. The Phase III study for the treatment of mild-to-moderate atopic dermatitis (AD) will soon be initiated, marking a pivotal milestone as this differentiated innovative topical drug advances into the confirmatory clinical stage.

View Details

Efficient Progress! Jiangsu Vcare Completed Patient Enrollment in Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor for Vitiligo

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has successfully completed patient enrollment in a Phase II clinical trial of VC005 Tablets, an independently developed second-generation highly selective JAK1 inhibitor, for the oral administration of non-segmental vitiligo (NSV).

View Details

Crack the Challenge of Alopecia！Jiangsu Vcare Secures IND Approval in China for VC005 Tablets, a Next-Generation Selective JAK1 Inhibitor, in Alopecia Areata

Recently, a major R&D milestone has been achieved for VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The project has officially obtained IND approval from the CDE of the NMPA of China, which is intended for the oral treatment of alopecia areata, bringing a brand-new therapeutic hope to patients suffering from hair loss.

View Details

Jiangsu Vcare Announces Positive Phase II Results for VC005 Topical Gel, a Second-Generation Highly Selective JAK1 Inhibitor, in the Treatment of Mild-to-Moderate Atopic Dermatitis (AD)

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.

View Details

Jiangsu Vcare’s Next-Generation TRK Inhibitor Eratrectinib (VC004) Selected for the “SPARK Plan” for Pediatric Oncology Drugs

Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.

View Details

Jiangsu Vcare Announces First Patient Enrollment in Phase Ⅱ Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.

View Details